Bristol-Myers Squibb Company
NYSE: BMY
$49.41
+$0.39 (+0.8%)
Closing Price on September 20, 2024
BMY Articles
Thursday's top analyst upgrades, downgrades and initiations include Applied Materials, Broadcom, Cisco Systems, Genworth Financial and SanDisk.
Published:
These are the top analyst upgrades and downgrades featured by 24/7 Wall St. for Thursday, October 16, 2014.
Published:
The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.
Published:
A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could be of the blockbuster variety.
Published:
A new report from the pharmaceutical team at Credit Suisse highlights four top stocks to buy for the remainder of 2014
Published:
ThinkstockBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) had approved the drug ELIQUIS, as a treatment for Deep...
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Tuesday, July 2, 2014. They include Alcatel-Lucent, Apple, FireEye, JDSU Uniphase and solar stocks.
Published:
In a new report, the analysts at health care boutique Leerink highlight numerous upcoming catalysts for some top stocks in the sector. Catalysts may move the stocks sharply either way, depending on...
Published:
These are the top Wall Street analyst upgrades, downgrades and initiations for Thursday, June 5, 2014. They include Apple, Lululemon, Microsoft, NBG, Twitter and Whole Foods.
Published:
A new report from the global equity strategy team at Credit Suisse maintains that the best defensive sector now is large cap pharmaceuticals. Here are their top large cap pharmaceuticals to buy now.
Published:
These are the top Wall Street analyst upgrades, downgrades and initiations seen on Thursday, May 15, 2014. They include Cisco Systems, Kinder Morgan, Rackspace, Twitter and L-3 Communications.
Published:
In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off that may provide investors some incredible outsized gains over the rest of the year.
Published:
Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large biotechnology stocks were not the lone...
Published:
In a new research report, Cowen analysts posted a list of some of the top new datapoints cited at the Cowen 2014 Healthcare Conference by large cap pharmaceutical companies concerning upcoming events...
Published:
Cadence Pharmaceuticals agreed Tuesday to be bought out by Mallinckrodt for $1.3 billion, or a more than 27% premium to Monday's closing share price. Some investors may anticipate a sweetened offer.
Published: